万泰生物(603392.SH)：重组呼吸道合胞病毒疫苗(CHO细胞)临床试验申请获受理

Core Viewpoint - Wantaibio (603392.SH) announced that its wholly-owned subsidiary, Xiamen Wantaicanghai Biotechnology Co., Ltd., has received the acceptance notice from the National Medical Products Administration (NMPA) for its clinical trial application of the "Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)" [1] Group 1 - The company has successfully submitted a clinical trial application for a new vaccine [1] - The acceptance of the application marks a significant step in the company's vaccine development process [1] - This development could potentially enhance the company's position in the biopharmaceutical industry [1]